Скачать или смотреть GLP-1 RAs May Reduce Risk of Retinal Vein Occlusion, Experts Say

At the 43rd Annual Scientific Meeting of the American Society of Retina Specialists, we sat down with Aleksandra Rachitskaya, MD, FASRS, and Kevin Allan, MD, PhD, from the Cleveland Clinic Cole Eye Institute, to discuss their presentation on GLP-1 RAs and their potential to reduce the risk of retinal vascular occlusions. Given the popularity of drugs like semaglutide in a wide range of specialties, ophthalmologists have begun to investigate their potential in eye care; Drs. Rachitskaya and Allan examined 53,000 patients over 3 years to discover a significant risk reduction in branch RVOs and RAOs.

“When these drugs were developed, nobody was thinking about the eye. You have to go back and study these effects to elucidate exactly what the contribution of these medications is. I see these large database studies as a stepping stone, right? We see this trend; we need to now go back to more granular analysis.”

Read the full article here: https://www.hcplive.com/view/glp-1-ra...

00:00:07 - Presentation overview
00:05:27 - Systemic risk factor modification versus direct retinal vascular effect
00:07:33 - Was the hazard reduction really due to the GLP-1 RA?
00:09:04 - Should ophthalmologists advocate for GLP-1 RAs for diabetes and early microvascular retinal changes?

#ophthalmology #RVO #ASRS2025